---
name: Genevoyager (Wuhan) Co., Ltd.
slug: genevoyager-2
site: both
website_domain: genevoyager.ltd
summary: Leading CRO/CDMO provider specializing in viral vectors, proteins, and vaccines with proprietary AAV manufacturing technology and cGMP-grade facilities operational since October 2023. Headquartered in Wuhan, China.
tagline: One-stop CRO/CDMO for viral vectors, proteins, and vaccines with proprietary AAV manufacturing platform.
founded_year: 2014
employee_count_band: 201-1000
employee_count_label: 201–1,000
parent_name: 
parent_slug: 
hq_country: CN
tier2_domain_verified: false
updated_at: 2026-06-16T07:02:20.941Z
services_count: 3
modalities_count: 3
indications_count: 0
locations_count: 1
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Genevoyager (Wuhan) Co., Ltd.

One-stop CRO/CDMO for viral vectors, proteins, and vaccines with proprietary AAV manufacturing platform.

Listed on cdmo.directory.

## Summary

Leading CRO/CDMO provider specializing in viral vectors, proteins, and vaccines with proprietary AAV manufacturing technology and cGMP-grade facilities operational since October 2023. Headquartered in Wuhan, China.

## At a glance

- Founded: 2014
- Employees (est.): 201–1,000
- HQ country: CN

## Services

- Regulatory Affairs
- Analytical Method Development & Validation
- Translational Research

## Modalities

- AAV / Viral Vector Platform
- Vaccine
- Biologics (Other)

## Locations

- Headquarters & cGMP Facility, Wuhan, Jiangxia District, China

## Certifications

- China; Identifier: High-tech Enterprise (高新技术企业); Source: https://genevoyager.ltd/about

## Long description

Genevoyager is a one-stop CRO/CDMO services provider focused on viral vectors, proteins, and therapeutic vaccines. The company operates a proprietary technology platform for large-scale AAV manufacturing and maintains cGMP-grade production facilities.

**Capabilities & Infrastructure:**
- Proprietary insect baculovirus system (One-Bac 4.0) for AAV expression with single-batch production capacity up to 1E+18 vg
- cGMP facility in Jiangxia District, Wuhan: 68,000 ft² with 5 viral vector production lines and 1 fill & finish line (operational since October 2023)
- Team of 300 professionals with expertise in viral vector R&D, preclinical efficacy evaluation, CMC development, QA/QC, and GMP production

**Subsidiary:**
BrainVTA (Wuhan) Co., Ltd., established 2014, operates as a CRO delivering viral reagents and customized technical services, with established presence in the academic market.

_Profile last updated: 2026-06-16T07:02:20.941Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.